| Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report? | 09/11 12:30 | zacks.com |
| Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) | 09/03 08:00 | globenewswire.com |
| Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference | 08/26 08:00 | globenewswire.com |
| Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs | 08/19 09:10 | seekingalpha.com |
| Esperion Therapeutics: Strategically Positioned To Grow | 08/16 04:09 | seekingalpha.com |
| Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript | 08/12 21:50 | seekingalpha.com |
| Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year | 08/12 12:47 | zacks.com |
| Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates | 08/12 08:11 | zacks.com |
| Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update | 08/12 06:00 | globenewswire.com |
| Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | 08/07 16:30 | globenewswire.com |